Lates News

ReLi Pharmaceutical: Estimated pre-tax expenses related to the acquisition of research and development intellectual property in the second quarter of fiscal year 2026 is 2.8 billion US dollars. Estimated research and development intellectual property related expenses for the second quarter of 2026 are $3.02 per share on both GAAP and non-GAAP basis.